your just now starting to figure this out? You come off as shocked with this company??? You have been around here for how many years?
in two years. from 30 cents to 1.60
Management you can say does a good job or bad job of being quiet, but everyone knew they were in line for the big task order, which is why the stock went from .30 to over $1.00. In order to move from 1.60 to 2.50, they need to show revenue growth and profitability. My guess is leading into the next quarter if they can show 17+ million or Q2 next year of 20 million. This will get them on new radars and pick up new coverage and THEN, the stock will move solidly into the 2.00 area.
If anyone listened to the past conference calls, this wasn't a total shock. Mgmt talked about potential acquisitions going forward, because the have a line of credit, so my guess is they do am acquisition before year end.
You are correct however, its not the main focus of INO. Ino has a very broad pipeline mostly focused on vaccines. My guess is Sal is still reguritating BS on here. He has posted over 300 times in less than a year.
Would be a great if they were working with oncs
They may have enough money till 2016 but they won't wait till 2016, you don't borrow money when you have $5 million left. Also their burn is going to start to increase as they start multiple trials. I think a cash raise will be good but it will slow down price movement.
Example: 1st quarter next year with some positive press, stock moves to $18/$20. Company rasise money at a discount $17.50. Typically stock trades down to flat for a period of time.
I think this stock moves 1st quarter next year as we start to get data read on these trials that are in proces.. However I would also be cautious as an S-1 is filied and if the stock price moves up, they raise money.
becareful: being realistic is almost the same as bashing the stock and the same people will jump all over you. sometimes its better just to join in with them to keep them quiet and make random comments like going to get bought out for $5.00 or easily over $1.00.
Not bad but not great either. My hope is that there is a lag from turning these contracts to execution to billing. I would like to see next quarter over 16 million to show some sequential growth going forward and of course the flow through to the bottom line.
Based upon that release, that sounds like a soft quarter and they threw in a little good with a little bad.
That is the rosy side! Maybe at Merck they were liked and their supervisor was giving bad reviews and trying to get them fired and they left while the getting was good?
curious: Do you go on Clovis Oncology and post welcome to the 40's down from 93 suckers.
or the other hundreds of stocks that have come down as the market is down over 7% in the last few weeks.
Out of curiousity, where does a start up biotech get money from, if you don't issue shares?
Bank? (with no assets or revenue)
Obviously your well educated with advanced degrees, please share with us and the company how you would have done it?